Evidence map›Paper›PMID 35340077›Full record

ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2022

Identification of ENPP1 Haploinsufficiency in Patients With Diffuse Idiopathic Skeletal Hyperostosis and Early-Onset Osteoporosis.

Hajime Kato, Anenya J Ansh, Ethan R Lester, Yuka Kinoshita, Naoko Hidaka, Yoshitomo Hoshino, Minae Koga, Yuki Taniguchi, Taisuke Uchida, Hideki Yamaguchi and 8 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Six cases ofJBMR plus · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Impact of theFrontiers in endocrinology · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Hajime KatoDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, Japan.ORCID 0000-0001-9178-7846
Anenya J AnshDepartment of Pathology, Yale University, New Haven, CT, USA.ORCID 0000-0002-0266-8392
Ethan R LesterDepartment of Pathology, Yale University, New Haven, CT, USA.ORCID 0000-0002-7539-0379
Yuka KinoshitaDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, Japan.ORCID 0000-0002-6583-0879
Naoko HidakaDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, Japan.ORCID 0000-0002-5450-2247
Yoshitomo HoshinoDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, Japan.
Minae KogaDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, Japan.
Yuki TaniguchiDepartment of Orthopedic Surgery, The University of Tokyo Hospital, Tokyo, Japan.ORCID 0000-0002-2329-123X
Taisuke UchidaDivision of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0003-4511-4901
Hideki YamaguchiDivision of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0003-2319-7988
Yo NiidaDivision of Genomic Medicine, Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Kanazawa, Japan.ORCID 0000-0001-5641-7962
Masamitsu NakazatoDivision of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0002-6270-2943
Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, Japan.ORCID 0000-0001-7401-2934
Noriko MakitaDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, Japan.ORCID 0000-0002-5722-115X
Toshinari TakamuraDepartment of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
Taku SaitoOsteoporosis Center, The University of Tokyo Hospital, Tokyo, Japan.ORCID 0000-0003-4911-3930
Demetrios T BraddockDepartment of Pathology, Yale University, New Haven, CT, USA.ORCID 0000-0002-0541-4689
Nobuaki ItoDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, Japan.ORCID 0000-0002-4071-5372
University of Tokyo Hospital · JPUniversity of Miyazaki · JPYale University · USKanazawa University · JP

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Renal Physiology and Phenotyping CoreP30DK079310 · NIDDK · YALE UNIVERSITY · PI SOMLO, STEFAN · 2008 to 2022
$16.8M
ENPP1 regulation of mammalian bone massR01AR080416 · NIAMS · YALE UNIVERSITY · PI DEMETRIOS BRADDOCK · 2022 to 2026
$2.3M
ENZYME THERAPY FOR CKD-MBD: BREAKING THE BARRIER OF VASCULAR CALCIFICATIONR01DK121326 · NIDDK · YALE UNIVERSITY · PI BRADDOCK, DEMETRIOS · 2020 to 2022
$680k
Inozyme PharmaJSPS KAKENHI JP21K09293NCATS NIH HHS UL1 TR001863NIAMS NIH HHS R01 AR080416NIDDK NIH HHS P30 DK079310NIDDK NIH HHS R01 DK121326NIH HHS R01 DK121326
6 · The paper itself

Abstract

Homozygous ENPP1 mutations are associated with autosomal recessive hypophosphatemic rickets type 2 (ARHR2), severe ossification of the spinal ligaments, and generalized arterial calcification of infancy type 1. There are a limited number of reports on phenotypes associated with heterozygous ENPP1 mutations. Here, we report a series of three probands and their families with heterozygous and compound heterozygous ENPP1 mutations. The first case (case 1) was a 47-year-old male, diagnosed with early-onset osteoporosis and low-normal serum phosphate levels, which invoked suspicion for hypophosphatemic rickets. The second and third cases were 77- and 54-year-old females who both presented with severe spinal ligament ossification and the presumptive diagnosis of diffuse idiopathic skeletal hyperostosis (DISH). Upon workup, fibroblast growth factor 23 (FGF23) was noted to be relatively high in case 2 and serum phosphorous was low-normal in case 3, and the diagnoses of X-linked hypophosphatemic rickets (XLH) and ARHR2 were considered. Genetic testing for genes related to congenital hypophosphatemic rickets was therefore performed, revealing heterozygous ENPP1 variants in cases 1 and 2 (case 1, c.536A>G, p.Asn179Ser; case 2, c.1352A>G, p.Tyr451Cys) and compound heterozygous ENPP1 variants in case 3 constituting the same variants present in cases 1 and 2 (c.536A>G, p.Asn179Ser and c.1352A>G, p.Tyr451Cys). Several in silico tools predicted the two variants to be pathogeneic, a finding confirmed by in vitro biochemical analysis demonstrating that the p.Asn179Ser and p.Tyr451Cys ENPP1 variants possessed a catalytic velocity of 45% and 30% compared with that of wild-type ENPP1, respectively. Both variants were therefore categorized as pathogenic loss-of-function mutations. Our findings suggest that ENPP1 mutational status should be evaluated in patients presenting with the diagnosis of idiopathic DISH, ossification of the posterior longitudinal ligament (OPLL), and early-onset osteoporosis. © 2022 American Society for Bone and Mineral Research (ASBMR).

Indexed as

Familial Hypophosphatemic RicketsHyperostosis, Diffuse Idiopathic SkeletalOsteoporosisRickets, HypophosphatemicFemaleFibroblast Growth FactorsHaploinsufficiencyHumansMalePhosphoric Diester HydrolasesPyrophosphatasesFibroblast Growth FactorsPhosphoric Diester HydrolasesPyrophosphatasesDIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSISEARLY-ONSET OSTEOPOROSISENTHESOPATHYFIBROBLAST GROWTH FACTOR 23OSSIFICATION OF THE POSTERIOR LONGITUDINAL LIGAMENTOSTEOPHYTE

Identifiers

PMID35340077
PMCPMC9177665
OpenAlexW4221126418

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.